首页> 美国卫生研究院文献>Molecules >Synthesis of 16 New Hybrids from Tetrahydropyrans Derivatives and Morita-Baylis-Hillman Adducts: In Vitro Screening against Leishmania donovani
【2h】

Synthesis of 16 New Hybrids from Tetrahydropyrans Derivatives and Morita-Baylis-Hillman Adducts: In Vitro Screening against Leishmania donovani

机译:从四氢吡喃衍生物和Morita-Baylis-Hillman加合物合成16种新杂种:针对利什曼原虫的体外筛选

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Leishmaniases are a group of neglected tropical diseases (NTDs) caused by protozoan parasites from >20 Leishmania species. Visceral leishmaniasis (VL), also known as kala-aza, is the most severe form of leishmaniasis, usually fatal in the absence of treatment in 95% of cases. The Morita-Baylis-Hillman adducts (MBHAs) are being explored as drug candidates against several diseases, one of them being leishmaniasis. We present here the design, synthesis and in vitro screening against Leishmania donovani of sixteen new molecular hybrids from analgesic/anti-inflammatory tetrahydropyrans derivatives and Morita-Baylis-Hillman adducts. First, acrylates were synthesized from analgesic/anti-inflammatory tetrahydropyrans using acrylic acid under TsOH as a catalyst (70%–75% yields). After the 16 new MBHAs were prepared in moderate to good yields (60%–95%) promoted by microwave irradiation or low temperature (0 °C) in protic and aprotic medium. The hybrids were evaluated in vitro on the promastigote stage of Leishmania donovani by determining their inhibitory concentrations 50% (IC50), 50% hemolysis concentration (HC50), selectivity index (HC50/IC50,), and comparing to Amphotericin B, chosen as the anti-leishmanial reference drug. The hybrid which presents the bromine atom in its chemical structure presents high leishmanicide activity and the high selectivity index in red blood cells (SIrb > 180.19), compared with the highly-toxic reference drug (SIrb = 33.05), indicating that the bromine hybrid is a promising compound for further biological studies.
机译:利什曼病是由超过20种利什曼原虫物种的原生动物寄生虫引起的一组被忽视的热带病(NTD)。内脏利什曼病(VL),也称为kala-aza,是最严重的利什曼病形式,通常在95%的情况下如果不进行治疗就会致命。人们正在探索将森田-贝利斯-希尔曼加合物(MBHA)作为抗多种疾病的候选药物,其中之一是利什曼病。我们在这里介绍设计​​,合成和体外筛选的利什曼原虫对来自镇痛/抗炎四氢吡喃衍生物和森田-贝利斯-希尔曼加合物的十六个新分子杂种。首先,在TsOH的催化下,使用丙烯酸由止痛/抗炎四氢吡喃类化合物合成丙烯酸酯(产率为70%至75%)。在质子和非质子介质中,通过微波辐照或低温(0°C)促进了16种新的MBHA的制备,以中等至良好的收率(60%–95%)进行了制备。通过确定其抑制浓度50%(IC50),50%溶血浓度(HC50),选择性指数(HC50 / IC50,)并与两性霉素B(选择为两性霉素B)进行比较,在杂种利什曼原虫的前鞭毛体阶段对其进行体外评估。抗leishmanial参考药物。与高毒性参比药物(SIrb = 33.05)相比,在化学结构中呈现溴原子的杂化物表现出高的利什曼杀菌活性和高选择性指数(SIrb> 180.19),表明溴杂化物是有望用于进一步生物学研究的化合物。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号